00000nam 2200000za 4500 9.836313 CaOODSP 20221107150854 cr ||||||||||| 180201s2017 onc ob f000 0 eng d 978-0-660-08486-2 CaOODSP eng n-cn--- HP40-1/2017-3E-PDF Canadian guidelines on sexually transmitted infections [electronic resource] : treatment of N. gonorrhoeae in response to the discontinuation of spectinomycin : alternative treatment guidance statement. Treatment of N. gonorrhoeae in response to the discontinuation of spectinomycin : alternative treatment guidance statement [Ottawa] : Public Health Agency of Canada, 2017. 4 p. Caption title. "May 2017." Includes bibliographical references. “The Public Health Agency of Canada (PHAC) has been informed that manufacturing of spectinomycin has been discontinued. This antimicrobial is therefore no longer available through Health Canada’s Special Access Program (SAP). In the face of increasing antimicrobial resistance in Neisseria gonorrhoeae, the discontinuation of spectinomycin has the potential to limit gonorrhea prevention and control efforts in Canada by further restricting treatment options. This guidance statement for alternative treatments for gonococcal infections was developed in consultation with the CGSTI Expert Working Group based on Canadian epidemiology and a rapid evidence review”--Issue, p. 1. gccst Sexually transmitted diseases gccst Medicine gccst Guidelines Public Health Agency of Canada. Lignes directrices canadiennes sur les infections transmissibles sexuellement. (CaOODSP)9.836314 Canadian guidelines on sexually transmitted infections (CaOODSP)9.840166 PDF 364 KB https://publications.gc.ca/collections/collection_2018/aspc-phac/HP40-1-2017-3-eng.pdf 170052